After what time interval are we justified to diagnose immune checkpoint inhibitor-mediated polymyalgia rheumatica?

IF 1.2 Q4 RHEUMATOLOGY

Reumatismo Pub Date : 2025-03-03 DOI:10.4081/reumatismo.2025.1823

Ciro Manzo, Marco Isetta

引用次数: 0

Abstract

Dear Editor, the number of cases of cancer patients diagnosed as having immune checkpoint inhibitor-mediated polymyalgia rheumatica has been steadily rising in published reports. However, the lack of a validated scale or algorithm is still a relevant methodological limit in diagnosing this nosologic entity...

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Reumatismo RHEUMATOLOGY-

CiteScore

2.10

自引率

7.10%

发文量

审稿时长

10 weeks

期刊介绍： Reumatismo is the official Journal of the Italian Society of Rheumatology (SIR). It publishes Abstracts and Proceedings of Italian Congresses and original papers concerning rheumatology. Reumatismo is published quarterly and is sent free of charge to the Members of the SIR who regularly pay the annual fee. Those who are not Members of the SIR as well as Corporations and Institutions may also subscribe to the Journal.